In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific's Buying Spree Continues, This Time in EP

Executive Summary

This month's $115 million cash deal to acquire electrophysiology company Cardiac Pathways Corp., makes five acquisitions for Boston Scientific already this year. Boston's dealmaking flurry is particularly notable given the relative inactivity of other large device companies on the acquisition front, and the cold shoulder the public market has given to the device sector. This deal reflects Boston's renewed commitment to electrophysiology, an area the company was thinking about exiting just a couple of years ago despite having a market-leading product. But it still remains to be seen whether this recent string of deals can turn around Boston Scientific and boost its flagging stock price.

You may also be interested in...



How To Fix A Guidant: Boston Scientific's Tobin Opens Playbook

Boston Scientific CEO Jim Tobin, in a series of addresses, defends his company's decision to spend $27.3 billion on Guidant Inc., warts and all. Defying criticism of the deal, Tobin lays out how Boston Scientific management corrected Guidant's problems--and why the new company will thrive.

Boston Scientific: An Acquiror Once More

Once an aggressive buyer of promising device technology, Boston Scientific's recent difficulties relegated it to the M&A sidelines; the company is back with a new string of acquisitions but a different gameplan.

Cardiac Pathways: Mapping a Tough Course in EP

Cardiac Pathways' strategy is to develop solutions for the most difficult cardiac rhythm problems, those for which even palliative treatments are limited. Armed with promising advanced technology, the company was one of the last through the 1996 medical device IPO window but since then has been paying the price for being slow to market. With FDA approval finally in hand, along with new management and additional financing obtained at a premium cost, Cardiac Pathways hopes to sustain itself long enough to finally take advantage of its technological lead by creating a new market treating patients who have few other options.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel